Similar Articles

  • A lump on the hip

    Morteza Khodaee, MD, MPH, Seth Mathern, MD, Wendy S. Madigosky, MD, MSPH and Jonathan T. Bravman, MD
    • Cleveland Clinic Journal of Medicine August 2017, 84 (8) 594-596;
    • DOI: https://doi.org/10.3949/ccjm.84a.16065

    • The patient had fallen on his hip while playing basketball about 2 weeks earlier.

  • Dislocation of the Hip in Myelodysplasia

    J. Ted Hartman, M.D
    • Cleveland Clinic Journal of Medicine April 1963, 30 (2) 67-72;

  • Intermittent Claudication of the Hip

    Fay A. LeFevre, M.D, George S. Phalen, M.D and Victor G. de Wolfe, M.D
    • Cleveland Clinic Journal of Medicine July 1953, 20 (3) 375-380;

  • A drug, a concept, and a clinical trial on trial

    Brian F. Mandell, MD, PhD
    • Cleveland Clinic Journal of Medicine July 2008, 75 (7) 470;

    • The ENHANCE trial, evaluating the addition of a second hypocholesterolemic drug (ezetimibe) to a statin using two surrogate end points in a relatively small number of patients, hit the national news when the two surrogates didn’t match up.

  • The ALLHAT Trial

    Donald G. Vidt, MD
    • Cleveland Clinic Journal of Medicine March 2003, 70 (3) 263-269;

    • Diuretics are unsurpassed in lowering blood pressure, reducing clinical events, tolerability, and low cost.

  • The ACUTE Trial

    Craig R. Asher, MD and Allan L. Klein, MD
    • Cleveland Clinic Journal of Medicine September 2002, 69 (9) 713-718;

    • A TEE-guided approach showed no advantage over conventional management in rates of embolic events, but shortened the anticoagulation course, allowed for earlier cardioversion, and caused fewer bleeding events.

  • The Mustt Trial

    Stephen Pavia, MD and Bruce L. Wilkoff, MD
    • Cleveland Clinic Journal of Medicine February 2001, 68 (2) 113-129;

    • Implantable defibrillators, but not antiarrhythmic drugs reduce the mortality rate in MI survivors at high risk.

  • The EPILOG Trial

    Matthew T. Roe, MD and David J. Moliterno, MD
    • Cleveland Clinic Journal of Medicine May 1998, 65 (5) 267-272;

    • The platelet glycoprotein Ilb/IIIa inhibitor abciximab, together with heparin in a low, weight-adjusted dose, markedly reduced the risk of acute ischemic complications during angioplasty, without increasing the risk of hemorrhage.

  • Clean air and total hip arthroplasty

    Carl L. Nelson, M.D and Alan Seth Greenwald, D.Phil.(Oxon)
    • Cleveland Clinic Journal of Medicine September 1972, 39 (3) 101-107;

  • Interpreting the COMET trial

    W.H. Wilson Tang, MD, Michael Militello, PharmD and Gary S. Francis, MD
    • Cleveland Clinic Journal of Medicine December 2003, 70 (12) 1081-1087;

    • Although survival was better with carvedilol than with immediate-release metoprolol tartrate, we must increase the use of any approved beta-blocker in heart failure.

Previous
Next